JNJ

Johnson & Johnson

253.79

Oct 19 • 3:59 PM ET -1.77 (-0.69%)

253.89

Aftermarket • 7:26 PM ET +0.10 (0.04%)

Healthcare Drug Manufacturers - General USA Mega NYSE

Today, 8:07 AMJ&J's TREMFYA maintains or improves perianal fistula remission through 48 weeks in Phase 3 Crohn's FUZION trial

Peers: ABBV MRK NVS AZN BMY PFE LLY SNY AMGN ABT

| Held by: VTI VOO IVV SPY VTV XLV VIG VYM VHT SPYM

Scroll to Statements

Index	DJIA, S&P 500
Market Cap	611.61B
Enterprise Value	639.89B
Income	16.09B
Sales	99.35B
Book/sh	35.28
Cash/sh	8.61
Dividend Est.	5.34 (2.10%)
Dividend TTM	5.28 (2.08%)
Dividend Ex-Date	Nov 24, 2026
Dividend Gr. 3/5Y	4.92% 5.25%
Payout	46.59%
Employees	140800
IPO	Sep 25, 1944

P/E	38.50
Forward P/E	21.75
PEG	2.41
P/S	6.16
P/B	7.19
P/C	29.46
P/FCF	27.50
EV/EBITDA	18.72
EV/Sales	6.44
Quick Ratio	0.81
Current Ratio	1.09
Debt/Eq	0.58
LT Debt/Eq	0.44
Option/Short	Yes / Yes

EPS (ttm)	6.59
EPS next Y	11.67
EPS next Q	2.91
EPS this Y	3.22%
EPS next Y	4.79%
EPS next 5Y	9.03%
EPS past 3/5Y	17.88% 14.90%
Sales past 3/5Y	5.56% 2.67%
EPS Y/Y TTM	-7.21%
Sales Y/Y TTM	7.81%
EPS Q/Q	-95.96%
Sales Q/Q	5.86%
Earnings	Oct 13 BMO
EPS/Sales Surpr.	2.68% 0.06%

Insider Own	0.12%
Insider Trans	-8.52%
Inst Own	77.25%
Inst Trans	0.11%
ROA	10.67%
ROE	25.74%
ROIC	13.16%
Gross Margin	74.91%
Oper. Margin	25.85%
Profit Margin	16.20%
SMA20	-2.62%
SMA50	-4.27%
SMA200	3.86%
Trades

Shs Outstand	2.41B
Shs Float	2.41B
Short Float	0.92%
Short Ratio	3.12
Short Interest	22.07M
52W High	281.07 -9.71%
52W Low	184.66 37.44%
Volatility	2.70% 2.10%
ATR (14)	6.05
RSI (14)	41.99
Beta	0.22
Rel Volume	1.25
Avg Volume	7.08M
Volume	8,847,837

Perf Week	-3.77%
Perf Month	-6.00%
Perf Quarter	1.27%
Perf Half Y	10.01%
Perf YTD	22.63%
Perf Year	31.35%
Perf 3Y	66.62%
Perf 5Y	54.87%
Perf 10Y	121.48%
Recom	1.89
Target Price	283.24
Prev Close	255.56
Price	253.79
Change %	-0.69%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-02-26	Resumed	UBS	Buy	$320
May-13-26	Upgrade	Leerink Partners	Market Perform → Outperform	$265
Apr-08-26	Resumed	TD Cowen	Buy	$250
Jan-28-26	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$262
Nov-13-25	Initiated	Scotiabank	Sector Outperform	$230
Oct-20-25	Upgrade	Daiwa Securities	Neutral → Outperform	$203
Oct-03-25	Upgrade	Wells Fargo	Equal Weight → Overweight	$212
Sep-23-25	Upgrade	Guggenheim	Neutral → Buy	$206
Jul-23-25	Upgrade	Erste Group	Hold → Buy
May-13-25	Downgrade	Leerink Partners	Outperform → Market Perform	$153
Dec-10-24	Resumed	BofA Securities	Neutral	$166
Nov-15-24	Initiated	Wolfe Research	Outperform	$190
Jul-23-24	Downgrade	Daiwa Securities	Outperform → Neutral	$160 → $150
May-30-24	Resumed	Goldman	Neutral	$160
Apr-18-24	Upgrade	HSBC Securities	Hold → Buy	$170
Dec-13-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$170 → $163
Dec-01-23	Upgrade	UBS	Neutral → Buy	$167 → $180
Oct-05-23	Initiated	RBC Capital Mkts	Outperform	$178
Sep-06-23	Initiated	HSBC Securities	Hold	$175
May-30-23	Resumed	Citigroup	Buy	$185

Show Previous Ratings

Today 09:46AM	Johnson & Johnson Reports 48-Week Tremfya Results in Phase 3 Crohn's Disease Fistula Study (InvestorsHub)
08:00AM	Johnson & Johnson announces new data showing TREMFYA (guselkumab) is the only IL-23 to deliver durable fistula remission through 48 weeks in Crohn's disease with perianal fistula (PR Newswire)
Oct-16-26 10:57PM	What Was Eli Lilly Telling You Before Its Stock Ran? (Trefis)
08:53PM	When Amgen's Forecast And Chart Say The Same Thing, Pay Attention (Trefis)
08:37PM	Gileads HIV Prevention Business Just Topped $1 Billion A Quarter. What Comes Next? (Trefis)
08:13PM	Loading…
08:13PM	Is Amgen Stock Increasing Your Market Risk? (Trefis)
03:52PM	Forget AI Stocks: Buy Med-Tech Stock ISRG Now for 40% Upside (Zacks)
09:38AM	Earnings Calendar and Analysis for This Week (Kiplinger)
Oct-15-26 05:23PM	3 Companies Raising Guidance This Earnings Season (Zacks)
05:01PM	Is Medtronic Stock A Buy Now That Sales Growth Has Picked Up? (Trefis)
03:46PM	How Has Merck's Story Changed? (Trefis)
03:18PM	Is Boston Scientific Stock Riskier Than It Was A Year Ago? (Trefis)
09:09AM	Where Could Johnson & Johnson's Next Growth Come From? (Trefis)
07:24AM	Earnings live updates: TSM reports record profits fueled by AI demand (Yahoo Finance)
Oct-14-26 09:47PM	How Much Downside Is Left In Liquidia Stock? (Trefis)
04:55PM	Loading…
04:55PM	What Could BSX Stock Be Worth In Three Years? (Trefis)
02:43PM	Johnson & Johnson CFO taps internal investment for medtech growth (CFO Dive)
09:48AM	Johnson and Johnson Stock Plunges 6% As Medical Device Sales Miss Wall Street Forecasts (TIKR)
09:31AM	J&J earnings set negative tone; Shkreli vs. the FTC (BioPharma Dive)
08:18AM	The Open Question Under Johnson & Johnson Stock's Price (Trefis)
04:24AM	SLS, IBRX Rise Premarket: Funds Raise Their Bets As J&J Stays On The Lookout For Deals (Stocktwits)
Oct-13-26 09:07PM	J&J Selloff Exposes Medtech Strain: Is Pharma Carrying Healthcare Stocks? (BeInCrypto) -5.73%
07:48PM	Is Amgen Stock Worth More Than Its Competitors? (Trefis)
07:10PM	UnitedHealth vs. Johnson & Johnson: Which Stock Is the Better Buy After Q3 Earnings? (Zacks)
04:08PM	Stocks Struggle Ahead of September CPI Report: Stock Market Today (Kiplinger)
04:03PM	Chips' Sixth Straight Loss Drags Nasdaq Into the Red (Barrons.com)
04:00PM	Nasdaq ends down as chipmakers fall and bank earnings roll in (Reuters)
03:59PM	What Does Bristol-Myers Squibb Offer That Pfizer Does Not? (Trefis)
03:24PM	What Is Eli Lilly Stock's Biggest Opportunity? (Trefis)
03:15PM	Stocks remain lower in final hour of trading. Energy and communication services limit market downside. (MarketWatch)
01:59PM	Loading…
01:59PM	Stock market today: Dow, S&P 500, Nasdaq fall as earnings season kicks off (Yahoo Finance)
01:41PM	Here's What's Dragging Down the Dow (Barrons.com)
01:09PM	J&J Takes a $5.5 Billion Talc Charge as MedTech Growth Slows From 7.7% to 2.5% (TIKR)
12:50PM	Johnson & Johnson Q3 2026 Earnings Call Summary (Moby)
12:34PM	J&Js medtech business slows again in Q3 (MedTech Dive)
12:14PM	Johnson & Johnson stock falls despite strong earnings as investors focus on medtech unit (Yahoo Finance)
11:41AM	Johnson & Johnson, Caterpillar share losses contribute to Dow's 134-point fall (MarketWatch)
11:34AM	Tremfya rescues J&Js immunology sales to fuel strong Q3 (Pharmaceutical Technology)
11:06AM	Johnson & Johnson Stock Slides After MedTech Miss (The Wall Street Journal)
10:17AM	Johnson & Johnson raises 2026 guidance as quarterly sales climb (Proactive)
09:55AM	Bank stocks rise on JPMorgan, Goldman earnings as chip stocks fall: AlphaCheck (Yahoo Finance)
09:14AM	Mixed Pre-Markets Greet Fresh Q3 Earnings Reports (Zacks)
08:55AM	Health Bellwether J&J Slumps As Middle East Conflict Hampers Medtech Sales (Investor's Business Daily)
08:38AM	Johnson & Johnson Beats Third-Quarter Earnings Estimates and Raises 2026 Revenue and Profit Outlook (InvestorsHub)
07:49AM	Tech Selloff Deepens as Bank Earnings Fuel Stock Market Rotation (Barrons.com)
07:00AM	Johnson & Johnson beats estimates, raises 2026 guidance (Investing.com)
06:51AM	Johnson & Johnson Hikes Earnings Guidance but Pharma Growth Masks a MedTech Stumble (Barrons.com)
06:37AM	Johnson & Johnson: Q3 Earnings Snapshot (Associated Press)
06:28AM	J&J Is Leaning Toward Spinning Out Its Hips-And-Knees Business (The Wall Street Journal)
06:25AM	Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2026 (Business Wire)
06:21AM	J&J beats earnings estimates; Middle East conflict weighs on medical device sales (Reuters)
06:20AM	Johnson & Johnson reports Q3 2026 results, raises 2026 guidance (Business Wire)
04:37AM	Nasdaq Futures Sink, Dow Rises Premarket As AI Chip Stocks Wobble Ahead Of Big Bank Earnings: MU, SNDK, NVTS, NVDA, SPCX, ASTS, UNH, V Stocks In Focus (Stocktwits)
03:53AM	Tuesday's earnings calendar (MarketWatch)
Oct-12-26 04:05PM	TREMFYA (guselkumab) demonstrated sustained clinical and endoscopic remission through 3 years in moderately to severely active Crohn's disease (PR Newswire)
04:05PM	New TREMFYA (guselkumab) study shows consistent perianal fistula remission across key Crohn's disease patient subgroups (PR Newswire)
02:33PM	Wall Street Is Shedding Risk Ahead of Earnings, Inflation Data (Barrons.com)
01:16PM	Has Medtronic Stock Become A Different Bet? (Trefis)
12:16PM	Stryker enters soft tissue robotics with $400M investment in CMR Surgical (MedTech Dive)
09:11AM	Big Week of Data: Inflation & Q3 Earnings (Zacks)
08:00AM	Heres How Much Johnson & Johnson Stock Is Expected to Move After Earnings (Investopedia)
07:29AM	After a Record-Setting Week, Wall Street Turns to Inflation Data and the First Big Earnings Reports (PR Newswire)
04:38AM	Welcome back to earnings season: What to watch this week (Yahoo Finance)
Oct-11-26 10:17PM	Stocktwits Pharma Pulse: JNJ Earnings, Cancer Updates And Two FDA Target Dates The Weeks Biotech Watchlist (Stocktwits)
Oct-09-26 08:47PM	Why Is Everyone Ignoring Gilead Stock's High Cash Yield? (Trefis)
02:12PM	Does The Move In Merck Stock Change Anything? (Trefis)
10:32AM	Boston sues J&J subsidiary over alleged patent infringement for cardiology device (Medical Device Network)
07:00AM	New Johnson & Johnson ICOTYDE (icotrokinra) long-term data demonstrate robust 2-year results in the treatment of adults and adolescents with plaque psoriasis (PR Newswire)
Oct-08-26 08:36PM	Should You Be Worried About Pfizer Stock? (Trefis)
10:51AM	Dow's nearly 150-point fall led by losses for shares of Amgen, Johnson & Johnson (MarketWatch)
09:03AM	What Would It Take For Amgen Stock To Move Higher? (Trefis)
09:00AM	Pharmas $500B patent problem will come in waves not as a cliff (Pharma Voice)
Oct-07-26 04:19PM	Moderna, Eli Lilly Lead Healthcare Stocks Higher on a Down Day for Markets (Investopedia)
12:13PM	Why You Should Think About Eli Lilly Stock Differently Now (Trefis)
Oct-06-26 10:02AM	What Could Lift ISRG Stock? (Trefis)
08:18AM	If The MiniMed Split-Off Stalls, What Happens To Your Medtronic Stock? (Trefis)
Oct-05-26 10:19AM	Has Eli Lilly Stock Peaked? (Trefis)
07:57AM	EADV26: Key late-stage readouts from the conference (Clinical Trials Arena)
Oct-02-26 04:18PM	Big Short Investor Predicts Imminent Market Correction: 3 Stocks to Buy in a Downturn (TIKR)
03:27PM	Why Medtronic's $4 Billion MiniMed Exchange Offer Is Losing Its Allure (Barrons.com)
06:27AM	How Has Pfizer's Story Changed? (Trefis)
06:00AM	Johnson & Johnson announces new ICOTYDE (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy (PR Newswire)
04:47AM	Are You Overpaying For Intuitive Surgical Stock Versus Its Rivals? (Trefis)
Oct-01-26 11:41AM	What Is The Options Market Telling Us About Eli Lilly Stock? (Trefis)
10:53AM	Focused Funds Can Help You Navigate a Top-Heavy Market (Barrons.com)
07:45AM	New Global Survey by Johnson & Johnson Finds Most Women Don't Connect Eye Health Changes with Menopause (Business Wire)
Sep-30-26 03:01PM	Was The Run In JNJ Stock Hiding In Plain Sight? (Trefis)
11:30AM	Microsoft vs. Johnson & Johnson: Which Dividend Will Pay You More in 10 Years? (TIKR)
11:29AM	Are You Overpaying For Pfizer Stock Versus Its Rivals? (Trefis)
10:43AM	What Is Merck Stock's Biggest Opportunity? (Trefis)
Sep-29-26 03:26PM	Do You Really Understand ISRG Stock's Risk? (Trefis)
02:57PM	Defensive Dividends: 3 Companies Investors Can Rely On (Zacks)
02:43PM	Is Eli Lilly Stock a Good Fit For Your Portfolio Risk? (Trefis)
02:42PM	Johnson & Johnson's psoriasis drug Icotyde could hit $4.5B in peak sales, BofA says (Proactive)
12:23PM	Management Raised the Bar For Eli Lilly Stock; Does The Chart Agree? (Trefis)
08:18AM	BofA Raises J&J Target but Sees Q3 Earnings 12% Below Street (GuruFocus.com)
08:03AM	Johnson & Johnson presents new data reinforcing sustained disease control and improved daily function achieved with IMAAVY (nipocalimab-aahu) in generalized myasthenia gravis (gMG) (PR Newswire)
Sep-28-26 04:33PM	$85 Billion And Counting: JNJ Stock's Steady Cash-Return Habit (Trefis)
03:09PM	How Big Could BSX Stock's Next Fall Be? (Trefis)
02:08PM	What Are Merck Stock Investors Overlooking? (Trefis)

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

CEO & ChairmanMr. Joaquin Duato

Executive VP & CFOMr. Joseph James Wolk CPA

Ph.D.Dr. John C. Reed M.D.

Executive VP & Worldwide Chairman of MedTechMr. Timothy Schmid

Controller & Chief Accounting OfficerMr. Robert J. Decker Jr.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Schmid Timothy	EVP, WW Chair, MedTech	Sep 02 '26	Option Exercise	144.99	33,597	4,871,389	47,974	Sep 04 09:08 AM
Schmid Timothy	EVP, WW Chair, MedTech	Sep 02 '26	Sale	274.74	33,597	9,230,440	25,447	Sep 04 09:08 AM
Schmid Timothy	Officer	Sep 02 '26	Proposed Sale	274.74	33,597	9,230,440		Sep 02 11:26 AM
Taubert Jennifer L	EVP, WWC. Innovative Medicine	Aug 17 '26	Option Exercise	115.67	15,000	1,735,050	209,451	Aug 18 06:31 PM
Taubert Jennifer L	EVP, WWC. Innovative Medicine	Aug 17 '26	Sale	263.36	15,000	3,950,400	194,451	Aug 18 06:31 PM
Taubert Jennifer L	Officer	Aug 17 '26	Proposed Sale	263.36	15,000	3,950,418		Aug 17 12:51 PM
Duato Joaquin	CEO and Chairman of the Board	Aug 13 '26	Option Exercise	115.67	123,291	14,261,070	399,258	Aug 14 04:35 PM
Duato Joaquin	CEO and Chairman of the Board	Aug 13 '26	Sale	261.17	123,291	32,199,927	275,967	Aug 14 04:35 PM
Duato Joaquin	Officer	Aug 13 '26	Proposed Sale	261.17	123,291	32,199,927		Aug 13 02:12 PM
Duato Joaquin	CEO and Chairman of the Board	Aug 05 '26	Sale	258.15	48,480	12,515,010	275,967	Aug 07 05:50 PM
Forminard Elizabeth	EVP, Chief Legal Officer	Aug 06 '26	Option Exercise	131.94	9,344	1,232,847	32,912	Aug 07 05:44 PM
Forminard Elizabeth	EVP, Chief Legal Officer	Aug 06 '26	Sale	257.00	15,918	4,090,960	16,994	Aug 07 05:44 PM
Forminard Elizabeth	Officer	Aug 06 '26	Proposed Sale	257.00	15,918	4,090,957		Aug 06 02:02 PM
Joaquin Duato	CEO, Chariman	Aug 05 '26	Proposed Sale	254.93	48,480	12,359,006		Aug 05 06:07 PM
Broadhurst Vanessa	EVP, Global Corp Affairs	Jul 20 '26	Option Exercise	130.77	23,054	3,014,701	46,057	Jul 21 05:27 PM
Broadhurst Vanessa	EVP, Global Corp Affairs	Jul 20 '26	Sale	251.27	23,054	5,792,686	23,003	Jul 21 05:27 PM
Broadhurst Vanessa	Officer	Jul 20 '26	Proposed Sale	251.27	23,054	5,792,689		Jul 20 01:35 PM
Wengel Kathryn E	EVP, Chief TO and Risk Officer	Jun 11 '26	Option Exercise	115.67	10,000	1,156,700	124,288	Jun 12 05:23 PM
Wengel Kathryn E	EVP, Chief TO and Risk Officer	Jun 11 '26	Sale	241.15	10,000	2,411,500	114,288	Jun 12 05:23 PM
Wengel Kathryn E	Officer	Jun 11 '26	Proposed Sale	240.15	10,000	2,401,539		Jun 11 01:44 PM
REED JOHN C	EVP, Innovative Medicine, R&D	May 01 '26	Option Exercise	0.00	25,255	0	35,913	May 04 04:58 PM
Decker Robert J	VP Corporate Controller	Feb 27 '26	Option Exercise	115.67	4,075	471,355	27,757	Mar 03 04:21 PM
Decker Robert J	VP Corporate Controller	Feb 27 '26	Sale	247.87	4,075	1,010,070	23,682	Mar 03 04:21 PM
Decker Robert J	Officer	Feb 27 '26	Proposed Sale	247.87	4,075	1,010,070		Feb 27 02:35 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 20 '26	Sale	245.66	1,322	324,763	25,447	Feb 23 05:20 PM
Schmid Timothy	Officer	Feb 20 '26	Proposed Sale	245.66	1,322	324,763		Feb 20 10:46 AM
Swanson James D.	EVP, CIO	Feb 13 '26	Option Exercise	132.73	51,418	6,824,543	47,211	Feb 18 09:12 PM
Swanson James D.	EVP, CIO	Feb 17 '26	Option Exercise	164.62	20,521	3,378,167	46,219	Feb 18 09:12 PM
Swanson James D.	EVP, CIO	Feb 15 '26	Option Exercise	0.00	1,201	0	26,007	Feb 18 09:12 PM
Swanson James D.	EVP, CIO	Feb 13 '26	Sale	243.73	41,559	10,129,312	25,020	Feb 18 09:12 PM
Swanson James D.	EVP, CIO	Feb 17 '26	Sale	242.70	20,521	4,980,447	25,698	Feb 18 09:12 PM
Wengel Kathryn E	EVP, Chief TO and Risk Officer	Feb 15 '26	Option Exercise	0.00	1,241	0	114,613	Feb 18 09:12 PM
Wengel Kathryn E	EVP, Chief TO and Risk Officer	Feb 13 '26	Option Exercise	0.00	14,357	0	120,096	Feb 18 09:12 PM
Mulholland Kristen	EVP, Chief HR Officer	Feb 15 '26	Option Exercise	0.00	994	0	20,081	Feb 18 09:12 PM
Mulholland Kristen	EVP, Chief HR Officer	Feb 13 '26	Option Exercise	0.00	4,012	0	20,286	Feb 18 09:12 PM
Wolk Joseph J	Exec VP, CFO	Feb 17 '26	Option Exercise	126.65	64,693	8,193,223	72,347	Feb 18 09:12 PM
Wolk Joseph J	Exec VP, CFO	Feb 15 '26	Option Exercise	0.00	3,849	0	39,778	Feb 18 09:12 PM
Wolk Joseph J	Exec VP, CFO	Feb 13 '26	Option Exercise	0.00	39,242	0	51,463	Feb 18 09:12 PM
Wolk Joseph J	Exec VP, CFO	Feb 17 '26	Sale	242.80	89,654	21,767,827	14,000	Feb 18 09:12 PM
Decker Robert J	VP Corporate Controller	Feb 15 '26	Option Exercise	0.00	683	0	23,777	Feb 18 09:12 PM
Decker Robert J	VP Corporate Controller	Feb 13 '26	Option Exercise	0.00	3,053	0	23,950	Feb 18 09:12 PM
REED JOHN C	EVP, Innovative Medicine, R&D	Feb 17 '26	Option Exercise	156.89	51,648	8,103,281	42,868	Feb 18 09:12 PM
REED JOHN C	EVP, Innovative Medicine, R&D	Feb 15 '26	Option Exercise	0.00	3,196	0	13,469	Feb 18 09:12 PM
REED JOHN C	EVP, Innovative Medicine, R&D	Feb 17 '26	Sale	243.00	53,931	13,105,233	10,658	Feb 18 09:12 PM
Forminard Elizabeth	EVP, Chief Legal Officer	Feb 15 '26	Option Exercise	0.00	2,024	0	24,112	Feb 18 09:11 PM
Forminard Elizabeth	EVP, Chief Legal Officer	Feb 13 '26	Option Exercise	0.00	14,357	0	29,591	Feb 18 09:11 PM
Taubert Jennifer L	EVP, WWC. Innovative Medicine	Feb 15 '26	Option Exercise	0.00	3,441	0	195,396	Feb 18 09:11 PM
Taubert Jennifer L	EVP, WWC. Innovative Medicine	Feb 13 '26	Option Exercise	0.00	28,714	0	206,318	Feb 18 09:11 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 18 '26	Option Exercise	121.17	22,623	2,741,335	40,394	Feb 18 09:11 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 15 '26	Option Exercise	0.00	2,054	0	27,217	Feb 18 09:11 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 13 '26	Option Exercise	0.00	4,877	0	26,994	Feb 18 09:11 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 18 '26	Sale	244.33	22,623	5,527,506	26,769	Feb 18 09:11 PM
Duato Joaquin	CEO and Chairman of the Board	Feb 15 '26	Option Exercise	0.00	8,187	0	326,407	Feb 18 09:11 PM
Duato Joaquin	CEO and Chairman of the Board	Feb 13 '26	Option Exercise	0.00	76,523	0	351,501	Feb 18 09:11 PM
Broadhurst Vanessa	EVP, Global Corp Affairs	Feb 15 '26	Option Exercise	0.00	1,018	0	29,470	Feb 18 09:11 PM
Broadhurst Vanessa	EVP, Global Corp Affairs	Feb 13 '26	Option Exercise	0.00	9,002	0	32,452	Feb 18 09:11 PM
Broadhurst Vanessa	EVP, Global Corp Affairs	Feb 17 '26	Sale	243.39	6,197	1,508,288	23,003	Feb 18 09:11 PM
Schmid Timothy	Officer	Feb 18 '26	Proposed Sale	244.33	22,623	5,527,546		Feb 18 11:14 AM
Broadhurst Vanessa	Officer	Feb 17 '26	Proposed Sale	243.39	6,197	1,508,300		Feb 17 04:10 PM
Swanson James D.	Officer	Feb 17 '26	Proposed Sale	242.70	20,521	4,980,510		Feb 17 02:52 PM
Wolk Joseph J	Officer	Feb 17 '26	Proposed Sale	242.80	89,654	21,767,965		Feb 17 02:43 PM
REED JOHN C	Officer	Feb 17 '26	Proposed Sale	243.00	53,931	13,105,233		Feb 17 12:44 PM
Swanson James D.	Officer	Feb 13 '26	Proposed Sale	243.73	41,559	10,129,246		Feb 13 02:33 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 06 '26	Option Exercise	101.87	15,571	1,586,218	32,460	Feb 10 09:46 PM
Mulholland Kristen	EVP, Chief HR Officer	Feb 06 '26	Option Exercise	101.87	5,625	573,019	19,744	Feb 09 07:42 PM
Wengel Kathryn E	EVP, Chief TO and Risk Officer	Feb 06 '26	Option Exercise	101.87	38,945	3,967,327	133,226	Feb 09 07:40 PM
Forminard Elizabeth	EVP, Chief Legal Officer	Feb 05 '26	Option Exercise	129.51	8,921	1,155,359	21,774	Feb 06 05:46 PM
Forminard Elizabeth	Officer	Feb 05 '26	Proposed Sale	237.90	6,226	1,481,195		Feb 05 04:31 PM
Duato Joaquin	CEO and Chairman of the Board	Jan 26 '26	Sale	221.23	100,000	22,122,893	30,852	Jan 28 06:07 PM
Joaquin Duato	CEO, Chariman	Jan 26 '26	Proposed Sale	220.14	100,000	22,014,000		Jan 26 04:57 PM
MORIKIS JOHN G	Director	Nov 26 '25	Buy	206.15	1,250	257,688	1,849	Dec 01 04:15 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

JNJ

Johnson & Johnson

Upgrade your Finviz experience